ACOUSORT AB |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.35 SEK | +1.47% |
|
+2.99% | -33.44% |
| 04-02 | AcouSort AB Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
| 2023 | AcouSort Raises Nearly SEK25 Million from Rights Offering | MT |
| Sales 2022 | 8.58M 785K 62.8M | Sales 2023 | 10.55M 964K 77.19M | Capitalization | 232M 21.18M 1.7B |
|---|---|---|---|---|---|
| Net income 2022 | -13M -1.19M -95.1M | Net income 2023 | -17M -1.55M -124M | EV / Sales 2022 | 18.8 x |
| Net cash position 2022 | 34.43M 3.15M 252M | Net cash position 2023 | 23.99M 2.19M 175M | EV / Sales 2023 | 19.7 x |
| P/E ratio 2022 |
-14.2
x | P/E ratio 2023 |
-12.1
x | Employees | 17 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 57.52% |
More Fundamentals
* Assessed data
More news
More press releases
| 1 day | +1.47% | ||
| 1 week | +2.99% | ||
| Current month | -15.85% | ||
| 1 month | +1.47% | ||
| 3 months | -31.46% | ||
| 6 months | -52.74% | ||
| Current year | -33.44% |
1 week
9.32
12.50
1 month
9.3212.95
Current year
9.3216.90
1 year
9.3228.60
3 years
9.3232.95
5 years
5.3232.95
10 years
5.3232.95
| Managers | Title | Age | Since |
|---|---|---|---|
Torsten Freltoft
CEO | Chief Executive Officer | 66 | 31/12/13 |
Gunnar Telhammar
DFI | Director of Finance/CFO | 63 | 31/12/15 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | - | 30/11/21 | |
| Founder | 63 | 31/12/10 | |
Martin Olin
CHM | Chairman | 55 | 27/04/21 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 10.35 | +1.47% | 40,698 |
| 25/04/24 | 10.2 | +5.37% | 49,147 |
| 24/04/24 | 9.68 | +1.47% | 41,556 |
| 23/04/24 | 9.54 | -0.83% | 37,409 |
| 22/04/24 | 9.62 | -4.28% | 42,993 |
Delayed Quote Nasdaq Stockholm, April 26, 2024 at 04:23 pm
More quotes
Acousort AB is a Sweden-based company engaged in the medical technology. The Company develops, produces and sells standalone laboratory products and integrated original equipment manufacturer (OEM) solutions where ultrasound is used to separate, wash and enrich cells, exosomes and other biological particles for research and diagnostics. Its product portfolio includes AcouWash and AcouTrap that are targeting separation, washing and enrichment applications within cell, bacteria and extracellular vesicle research. In addition, the Company develops proprietary bioanalytical and clinical applications based on acoustophoresis, and offers custom-developed acoustophoresis applications.
Calendar
29/04/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -33.44% | 14.1M | |
| +1.51% | 42.75B | |
| +49.22% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- ACOU Stock
